Description: Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Home Page: www.larimartx.com
LRMR Technical Analysis
Three Bala Plaza East
Bala Cynwyd,
PA
19004
United States
Phone:
844 511 9056
Officers
| Name | Title |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, Pres & Director |
| Mr. Michael Celano CPA | Sec. & CFO |
| Mr. John Berman | VP of Fin. & Operations |
| Ms. Jennifer Spokes Johansson | VP of Regulatory Affairs & Counsel |
| Dr. Nancy M. Ruiz | Chief Medical Officer |
| Mr. Francis Michael Conway | VP & Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6336 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-06-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |